Antibacterial, Antibiofilm, and Antiviral Farnesol-Containing Nanoparticles Prevent Staphylococcus aureus from Drug Resistance Development

Keyphrases

• Nanoparticles 100%
• Staphylococcus Aureus 100%
• Drug Resistance 100%
• Farnesol 100%
• Antibacterial-antibiofilm 100%
• Resistance Development 100%
• Antibacterial Properties 66%
• Induced Resistance 66%
• Health Problems 33%
• Antibiotics 33%
• S. Aureus Biofilm 33%
• Multidrug-resistant 33%
• Antimicrobial Resistance 33%
• Active Agent 33%
• Increased Mortality 33%
• Financial Burden 33%
• Persistent Infection 33%
• Nanoformulation 33%
• Novel Nanoparticles 33%
• Pharmaceutics 33%
• Antiviral Properties 33%
• Biofilm Community 33%
• Skin Infection 33%
• Anti-inflammatory Cytokines 33%
• Skin Tissue 33%
• Mature Biofilm 33%
• Multidrug 33%
• Bioproducts 33%
• Conventional Antibiotics 33%
• Nano-antimicrobials 33%
• SARS-CoV-2 Spike Protein 33%
• Skin Tissue Models 33%
• Antibiotic-free 33%
• 3D Skin 33%
• Tissue Irritation 33%
• High-frequency Ultrasound 33%
• Natural Bactericide 33%
• Nano-entities 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanoparticle 100%
• Antiinfective Agent 100%
• Antivirus Agent 100%
• Staphylococcus Aureus 100%
• Drug Resistance 100%
• Farnesol 100%
• Antibiotic Agent 50%
• Antimicrobial Resistance 25%
• Antibiotics 25%
• Anti-Inflammatory Drug 25%
• Cytokine 25%
• SARS Coronavirus 25%
• Persistent Infection 25%
• Bactericide 25%
• Skin Infection 25%
• Pharmaceutics 25%

Immunology and Microbiology

• Biofilm 100%
• Drug Resistance 100%
• Staphylococcus Aureus 100%
• Antibacterial Activity 66%
• Severe Acute Respiratory Syndrome Coronavirus 2 33%
• Antimicrobial Resistance 33%
• Inflammatory Cytokine 33%
• Secretion (Process) 33%
• Spike 33%
• Antiviral Activity 33%